Primary endocrine therapy as a treatment for older women with operable breast cancer - A comparison of randomised controlled trial and cohort study findings

Conclusions: Guidelines to aid selection are needed but PET should be reserved for patients with reduced predicted life expectancy (e.g. less than five years), with AIs being preferable over Tamoxifen.